22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › CULLINAN THERAPEUTICS INC. › 2024-2025

CULLINAN THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and CULLINAN THERAPEUTICS INC.’s Form 8-K, filed June 12, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Reported items
  • 157Asset managers, any item
  • 1,226Fund votes
  • June 12, 2025Meeting date

Results at a glance

Meeting of June 12, 2025: 5 items on CULLINAN THERAPEUTICS INC.’s Form 8-K, filed June 12, 2025: 2 approved · 3 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore CULLINAN THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by CULLINAN THERAPEUTICS INC.

These tallies are CULLINAN THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CULLINAN THERAPEUTICS INC. — official shareholder meeting results, meeting held June 12, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Anthony Rosenberg 47,044,236---- 1,926,3703,138,175 96%Passed (calculated)—
Elect Director: David P. Ryan, M.D. 47,241,434---- 1,729,1723,138,175 96%Passed (calculated)—
Elect Director: Mary Thistle 48,835,369---- 135,2373,138,175 99.7%Passed (calculated)—
2. Ratification of Appointment of Independent Registered Accounting Firm 51,936,984157,47714,320 --0 99.7%Approved—
3. Advisory Vote on Executive Compensation 46,956,0421,999,88914,675 --3,138,175 96%Approved—

Source: CULLINAN THERAPEUTICS INC., Form 8-K, filed with the SEC on June 12, 2025 — read the filing on EDGAR.

How asset managers voted at the CULLINAN THERAPEUTICS INC. 2024-2025 meeting

157 asset managers disclosed a vote on at least one CULLINAN THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CULLINAN THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Anthony Rosenberg

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 47,044,236WITHHELD: 1,926,370
Details: description as filed, official tally, votes by 48 asset managers

Description as filed by funds: Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2028: Anthony Rosenberg

CULLINAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Anthony Rosenberg”): 47,044,236 for, 1,926,370 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 8,303,280 for, 1,189,443 withheld.

FOR
FOR: 8,303,280WITHHOLD: 1,189,443
Largest asset managers voting on “Election of the following individuals nominated to serve as Class II directors, for a three-year term ending a” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,954,3480 00For
FRANKLIN STRATEGIC SERIES1,268,9940 00For
BlackRock1,224,1020 00For
Fidelity1,123,7150 00For
AllianceBernstein00 0950,416Withhold
Charles Schwab427,1140 00For
State Street260,6220 00For
Dimensional201,2610 00For
TIAA187,3900 00For
Principal00 0175,879Withhold
Equitable91,4450 044,060Mixed
American Century115,5140 00For
Lincoln Financial73,3440 00For
Northern Trust42,8620 00For
Tema ETF Trust39,6050 00For
Global X30,1830 00For
AIG/SunAmerica26,6970 00For
Direxion Shares ETF Trust25,1030 00For
ProShares22,9040 00For
John Hancock20,9340 00For
Brighthouse19,0020 00For
Pacific Life17,3350 00For
Voya14,3970 00For
ETF Series Solutions14,1070 00For
AuguStar00 013,848Withhold

Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).

Elect Director: David P. Ryan, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 47,241,434WITHHELD: 1,729,172
Details: description as filed, official tally, votes by 48 asset managers

Description as filed by funds: Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2028: David P. Ryan, M.D.

CULLINAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: David P. Ryan, M.D.”): 47,241,434 for, 1,729,172 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 8,308,520 for, 1,184,203 withheld.

FOR
FOR: 8,308,520WITHHOLD: 1,184,203
Largest asset managers voting on “Election of the following individuals nominated to serve as Class II directors, for a three-year term ending a” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,954,3480 00For
FRANKLIN STRATEGIC SERIES1,268,9940 00For
BlackRock1,224,1020 00For
Fidelity1,123,7150 00For
AllianceBernstein00 0950,416Withhold
Charles Schwab427,1140 00For
State Street260,6220 00For
Dimensional201,2610 00For
TIAA187,3900 00For
Principal00 0175,879Withhold
Equitable91,4450 044,060Mixed
American Century115,5140 00For
Lincoln Financial73,3440 00For
Northern Trust42,8620 00For
Tema ETF Trust39,6050 00For
Global X30,1830 00For
AIG/SunAmerica26,6970 00For
Direxion Shares ETF Trust25,1030 00For
ProShares22,9040 00For
John Hancock20,9340 00For
Brighthouse19,0020 00For
Pacific Life17,3350 00For
Voya14,3970 00For
ETF Series Solutions14,1070 00For
AuguStar00 013,848Withhold

Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).

Elect Director: Mary Thistle

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 48,835,369WITHHELD: 135,237
Details: description as filed, official tally, votes by 48 asset managers

Description as filed by funds: Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2028: Mary Thistle

CULLINAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mary Thistle”): 48,835,369 for, 135,237 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 9,478,875 for, 13,848 withheld.

FOR
FOR: 9,478,875WITHHOLD: 13,848
Largest asset managers voting on “Election of the following individuals nominated to serve as Class II directors, for a three-year term ending a” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,954,3480 00For
FRANKLIN STRATEGIC SERIES1,268,9940 00For
BlackRock1,224,1020 00For
Fidelity1,123,7150 00For
AllianceBernstein950,4160 00For
Charles Schwab427,1140 00For
State Street260,6220 00For
Dimensional201,2610 00For
TIAA187,3900 00For
Principal175,8790 00For
Equitable135,5050 00For
American Century115,5140 00For
Lincoln Financial73,3440 00For
Northern Trust42,8620 00For
Tema ETF Trust39,6050 00For
Global X30,1830 00For
AIG/SunAmerica26,6970 00For
Direxion Shares ETF Trust25,1030 00For
ProShares22,9040 00For
John Hancock20,9340 00For
Brighthouse19,0020 00For
Pacific Life17,3350 00For
Voya14,3970 00For
ETF Series Solutions14,1070 00For
AuguStar00 013,848Withhold

Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 46,956,042AGAINST: 1,999,889
Details: description as filed, official tally, votes by 157 asset managers

Description as filed by funds: PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.

CULLINAN THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 46,956,042 for, 1,999,889 against — passed, per its Form 8-K filed June 12, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three — Advisory Vote on Executive Compensation The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers by the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 48 asset managers voting on “PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,954,3480 00For
FRANKLIN STRATEGIC SERIES1,268,9940 00For
BlackRock1,224,1020 00For
Fidelity1,123,7150 00For
AllianceBernstein0950,416 00Against
Charles Schwab427,1140 00For
State Street260,55270 00For
Dimensional201,2610 00For
TIAA187,3900 00For
Principal0175,879 00Against
Equitable91,44544,060 00Mixed
American Century0115,514 00Against
Lincoln Financial73,3440 00For
Northern Trust42,8620 00For
Tema ETF Trust39,6050 00For
Global X30,1830 00For
AIG/SunAmerica26,6970 00For
Direxion Shares ETF Trust25,1030 00For
ProShares22,9040 00For
John Hancock20,9340 00For
Brighthouse19,0020 00For
Pacific Life17,3350 00For
Voya14,3970 00For
ETF Series Solutions14,1070 00For
AuguStar00 13,8480Abstain

Fund voting reports, all 48 managers: 8,186,423 for, 1,292,452 against, 13,848 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 127 asset managers voting on “PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
MPM BioImpact LLC7,648,2680 00For
BVF INC/IL5,750,6830 00For
DEERFIELD MANAGEMENT COMPANY, L.P.3,650,8930 00For
Lynx1 Capital Management LP3,339,8160 00For
Blue Owl Capital Holdings LP2,435,9480 00For
FRANKLIN ADVISERS INC2,180,8710 00For
ORBIMED ADVISORS LLC1,923,8550 00For
RTW INVESTMENTS, LP1,705,9600 00For
AllianceBernstein01,599,875 00Against
BlackRock1,412,68710,124 00For
Kynam Capital Management, LP00 01,417,426Withhold
VR Adviser, LLC1,379,9650 00For
Citadel1,301,4960 00For
GEODE CAPITAL MANAGEMENT, LLC1,246,2820 00For
State Street1,229,522281 00For
Siren, L.L.C.1,044,0940 00For
BRAIDWELL LP834,6510 00For
Rock Springs Capital Management LP644,6330 00For
Foresite Capital Management VI LLC634,5580 00For
MARSHALL WACE, LLP575,7120 00For
Charles Schwab441,9080 00For
Northern Trust261,5560 00For
Nuveen188,0300 00For
Dimensional171,1640 00For
Voss Capital, LP155,3510 00For

Institutional-manager reports, all 127 managers: 41,202,542 for, 1,826,216 against, 1,417,426 withheld, 14,578 1 year. Showing the 25 largest; every one is in the interactive database (link above).

Proposal to vote, on an advisory basis, on the frequency of future advisory votes on our named executive officer…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

65% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: description as filed, votes by 153 asset managers

Description as filed by funds: PROPOSAL TO VOTE, ON AN ADVISORY BASIS, ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON OUR NAMED EXECUTIVE OFFICER COMPENSATION.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 48 asset managers voting on “PROPOSAL TO VOTE, ON AN ADVISORY BASIS, ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON OUR NAMED EXECUTIVE OFFIC” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00--
FRANKLIN STRATEGIC SERIES00 00--
BlackRock00 00--
Fidelity00 00--
AllianceBernstein00 00--
Charles Schwab00 00--
State Street00 00--
Dimensional00 00--
TIAA00 00--
Principal00 00--
Equitable00 00--
American Century00 00--
Lincoln Financial30,7040 00For
Northern Trust00 00--
Tema ETF Trust00 00--
Global X00 00--
AIG/SunAmerica00 00--
Direxion Shares ETF Trust00 00--
ProShares00 00--
John Hancock00 00--
Brighthouse00 00--
Pacific Life00 00--
Voya00 00--
ETF Series Solutions00 00--
AuguStar00 13,8480Abstain

Fund voting reports, all 48 managers: 30,704 for, 13,848 abstained, 9,222,453 1 year, 225,718 3 year. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 123 asset managers voting on “PROPOSAL TO VOTE, ON AN ADVISORY BASIS, ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON OUR NAMED EXECUTIVE OFFIC” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
MPM BioImpact LLC00 00--
BVF INC/IL00 00--
DEERFIELD MANAGEMENT COMPANY, L.P.00 00--
Lynx1 Capital Management LP00 00--
Blue Owl Capital Holdings LP2,435,9480 00For
FRANKLIN ADVISERS INC00 00--
ORBIMED ADVISORS LLC00 00--
RTW INVESTMENTS, LP00 00--
AllianceBernstein00 00--
BlackRock00 00--
Kynam Capital Management, LP00 01,417,426Withhold
VR Adviser, LLC00 00--
Citadel00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
State Street00 00--
Siren, L.L.C.00 00--
BRAIDWELL LP00 00--
Rock Springs Capital Management LP00 00--
Foresite Capital Management VI LLC00 00--
MARSHALL WACE, LLP00 00--
Charles Schwab00 00--
Northern Trust00 00--
Nuveen00 00--
Dimensional00 00--
Voss Capital, LP155,3510 00For

Institutional-manager reports, all 123 managers: 2,607,975 for, 20 against, 1,417,426 withheld, 40,201,175 1 year, 171,164 3 year. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

99.7% Approved · of votes cast

FOR 99.7%
FOR: 51,936,984AGAINST: 157,477

Prior year: 98.7% for (June 26, 2024 meeting) ▲ 1.0 pts

Details: description as filed, official tally, votes by 48 asset managers

Description as filed by funds: Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2025.

CULLINAN THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Accounting Firm”): 51,936,984 for, 157,477 against — passed, per its Form 8-K filed June 12, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two — Ratification of Appointment of Independent Registered Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2025 by the following votes:”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 9,478,765 for, 110 against, 13,848 abstained.

FOR
FOR: 9,478,765AGAINST: 110ABSTAIN: 13,848
Largest asset managers voting on “Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics' independent registered public account” at CULLINAN THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,954,3480 00For
FRANKLIN STRATEGIC SERIES1,268,9940 00For
BlackRock1,224,1020 00For
Fidelity1,123,7150 00For
AllianceBernstein950,4160 00For
Charles Schwab427,1140 00For
State Street260,6220 00For
Dimensional201,2610 00For
TIAA187,3900 00For
Principal175,8790 00For
Equitable135,5050 00For
American Century115,5140 00For
Lincoln Financial73,3440 00For
Northern Trust42,8620 00For
Tema ETF Trust39,6050 00For
Global X30,1830 00For
AIG/SunAmerica26,6970 00For
Direxion Shares ETF Trust25,1030 00For
ProShares22,9040 00For
John Hancock20,9340 00For
Brighthouse19,0020 00For
Pacific Life17,3350 00For
Voya14,3970 00For
ETF Series Solutions14,1070 00For
AuguStar00 13,8480Abstain

Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).

Largest CULLINAN THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 58,698,919 shares outstanding at the time of that meeting.

Fund voting reports: top CULLINAN THERAPEUTICS INC. shareholders by shares voted on “PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 5.03%
2FRANKLIN STRATEGIC SERIES 2.16%
3BlackRock 2.09%
4Fidelity 1.91%
5AllianceBernstein 1.62%
6Charles Schwab 0.73%
7State Street 0.44%
8Dimensional 0.34%
9TIAA 0.32%
10Principal 0.30%
Institutional-manager reports: top CULLINAN THERAPEUTICS INC. shareholders by shares voted on “PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.”, 2024-2025
#Asset manager % of shares outstanding
1MPM BioImpact LLC 13.03%
2BVF INC/IL 9.80%
3DEERFIELD MANAGEMENT COMPANY, L.P. 6.22%
4Lynx1 Capital Management LP 5.69%
5Blue Owl Capital Holdings LP 4.15%
6FRANKLIN ADVISERS INC 3.72%
7ORBIMED ADVISORS LLC 3.28%
8RTW INVESTMENTS, LP 2.91%
9AllianceBernstein 2.73%
10BlackRock 2.42%

Reported CULLINAN THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

CULLINAN THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BVF PARTNERS L P/IL6,161,469 10.50%Schedule 13G, filed May 15, 2026
LYNX1 CAPITAL MANAGEMENT LP5,766,090 9.82%Schedule 13G, filed November 14, 2025
BlackRock4,220,862 7.19%Form 13F, quarter ended March 31, 2025
Vanguard Group3,039,731 5.18%Form 13F, quarter ended March 31, 2025
Deerfield Mgmt, L.P.2,927,013 4.99%Schedule 13G, filed November 13, 2025
Citadel Advisors2,769,645 4.72%Form 13F, quarter ended March 31, 2025
Franklin Templeton2,219,761 3.78%Form 13F, quarter ended March 31, 2025
Kenneth Griffin1,988,907 3.39%Schedule 13G, filed November 14, 2025
State Street1,752,679 2.99%Form 13F, quarter ended March 31, 2025
Dimensional Fund Advisors1,303,221 2.22%Form 13F, quarter ended March 31, 2025

Percentages above are of 58,698,919 shares outstanding, as reported by CULLINAN THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At CULLINAN THERAPEUTICS INC.'s shareholder meeting held June 12, 2025, in the 2024-2025 proxy season, 157 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,226 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION. — CULLINAN THERAPEUTICS INC.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CULLINAN THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CULLINAN THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

CULLINAN THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “CULLINAN THERAPEUTICS (CGEM) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/cullinan-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.